Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.03 CAD
Change Today 0.00 / 0.00%
Volume 0.0
PBS On Other Exchanges
As of 10:11 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

pacgen life science corp (PBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/6/15 - C$0.05
52 Week Low
12/8/14 - C$0.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PACGEN LIFE SCIENCE CORP (PBS)

Related News

No related news articles were found.

pacgen life science corp (PBS) Related Businessweek News

No Related Businessweek News Found

pacgen life science corp (PBS) Details

Pacgen Life Science Corporation, a life science technology company, focuses on the commercialization of biomedical products and services. It offers lab equipment, such as Fit X1 401, an automated, high-precision pipetting system designed to replace the manual process of PCR/qPCR sample preparation; electronic pipettes; and A + Pipette Controller, an electronic pipette controller designed for use with graduated and volumetric glass and plastic pipets. The company also provides reagent kits. In addition, it develops novel therapeutic drug candidates. Its product candidates include PAC-113, an anti-fungal drug, which has completed a Phase IIb clinical trial for the treatment of oral Candidiasis; and PAC-G31P, a novel peptide therapeutic, which is in preclinical studies for the treatment of inflammatory diseases characterized by non-beneficial neutrophil. The company has license agreement with Demegen, Inc. to expand its exclusive worldwide rights and license to PAC-113 for additional indications, including vaginal, dermatological, and ophthalmic applications. It was formerly known as Pacgen Biopharmaceuticals Corporation and changed its name to Pacgen Life Science Corporation in April 2012. The company was founded in 2004 and is headquartered in Vancouver, Canada.

Founded in 2004

pacgen life science corp (PBS) Top Compensated Officers

Co-Founder, Chairman, Interim Chief Executive...
Total Annual Compensation: --
Chief Financial Officer, Secretary and Member...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

pacgen life science corp (PBS) Key Developments

Pacgen Life Science To Move From Tier 1 To Tier 2

In accordance with Policy 2.5, the Pacgen Life Science Corporation has not met the requirements for a Tier 1 company. Therefore, effective April 10, 2015, the Company's Tier classification will change from Tier 1 to Classification Tier 2.

Pacgen Life Science Corporation, Annual General Meeting, Mar 12, 2015

Pacgen Life Science Corporation, Annual General Meeting, Mar 12, 2015., at 13:00 Pacific Standard Time. Location: Suite1300-777 Dunsmuir Street. Agenda: To receive the financial statements of the company for the fiscal year ended March 31, 2014 and the report of the auditors thereon; to elect the directors of the company to hold office until their successors are elected at the next annual meeting of the company; to appoint the auditors of the company to hold office until the next annual meeting of the company and to authorize the directors to fix the remuneration to be paid to the auditors; to re-approve the company's 10% rolling stock option plan and certain amendments thereto; and to transact such other business as may properly be brought before the meeting.

Pacgen Life Science Corporation Enters Agreement with General Biologicals Corporation

Pacgen Life Science Corporation announced that it has entered an agreement (the agreement') with General Biological Corporation ('GBC') pursuant to which the company will sublicense to GBC the right to develop and commercialize PAC-113, a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in human saliva. Under the terms of the Agreement, Pacgen will sublicense to GBC its worldwide exclusive right to develop and commercialize prescription and non-prescription pharmaceutical products containing PAC- 113 or one or more related peptides for the treatment of any oral condition (excluding transitional skin- mucous membrane areas), as well as vaginal, dermatological and ophthalmic conditions. In exchange, GBC will pay Pacgen both an upfront payment and minimum annual royalty payments. GBC will also pay Pacgen milestone payments and royalty payments linked to marketing approvals and product sales, respectively. Completion of the transaction contemplated by the Agreement is subject to approval by the TSX Venture Exchange and approval by the shareholders of the Company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBS:CN C$0.03 CAD 0.00

PBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBS.
View Industry Companies

Industry Analysis


Industry Average

Valuation PBS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 92.0x
TEV/Sales 13.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACGEN LIFE SCIENCE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at